Prognoz
For SCLC, the overall prognosis is poor. The median survival time for limited-stage SCLC is 00 months, with a 0-year survival rate of 00%. Patients with extensive-stage SCLC do especially poorly, with a 0-year survival rate of < 0%.
For NSCLC, the 0-year survival rate varies by stage, from 00 to 00% for patients with stage I disease to 0 to 00 % for patients with stage IV disease
Prevention
No active interventions to prevent lung cancer are proven to be effective except for smoking cessation.
Çeviri yapılırken hata oluştu. Tekrar hemen çevir butonuna tıklayınız.